Compound medicine composition for treating dyslipidemia and AS (artherosclerosis)

A technology of dyslipidemia and drugs, applied in the field of medicine, can solve problems that have not been used to improve dyslipidemia

Active Publication Date: 2015-06-03
CHINA PHARM UNIV
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CDP and BSA have no research re

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicine composition for treating dyslipidemia and AS (artherosclerosis)
  • Compound medicine composition for treating dyslipidemia and AS (artherosclerosis)
  • Compound medicine composition for treating dyslipidemia and AS (artherosclerosis)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Therapeutic effect of drugs on hyperlipidemia model in mice induced by high-fat diet

[0027] Compare the therapeutic effect of SAR combined with pCPA, CDP, BSA, and each alone on the hyperlipidemia model of rats fed with high-fat diet, so as to verify the synergistic effect of combined administration of SAR, pCPA, CDP, and BSA on the treatment of dyslipidemia effect.

[0028] 2.1 Experimental method

[0029] (1) Animal handling

[0030] 180 male ICR mice were randomly divided into 18 groups (10 in each group): control group, dyslipidemia model group, dyslipidemia model SAR treatment group, dyslipidemia model SAR+pCPA compound treatment group (SAR: pCPA was formulated according to different weights). 4 kinds of compound prescriptions compared with each other), dyslipidemia model pCPA treatment group, dyslipidemia model SAR+CDP compound treatment group (SAR:CDP is 4 kinds of compound according to different weight ratios), dyslipidemia model CDP treatment group, dyslipi...

Embodiment 2

[0074] Therapeutic effect of drugs on DEX-induced dyslipidemia rat model

[0075] Compare the therapeutic effects of SAR combined with pCPA, CDP, BSA, and each alone on the DEX-induced dyslipidemia model in rats (simulating the situation of long-term mental stress or chronic stress in humans), so as to re-verify the relationship between SAR and pCPA, CDP , The synergistic effect of BSA combined administration on the treatment of dyslipidemia.

[0076] 3.1 Experimental method

[0077] (1) Animal handling

[0078] 144 male SD rats were randomly divided into 18 groups (8 rats in each group): control group, model group, model SAR treatment group, model SAR+pCPA compound treatment group (SAR: 4 kinds of compounds of pCPA in different weight ratios) , model pCPA treatment group, model SAR+CDP compound treatment group (SAR: CDP in different weight ratios of 4 kinds of compounds), model CDP treatment group, model SAR+BSA compound treatment group (SAR: BSA in different weight ratios ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine, in particular to a medical application of a compound medicine composition of 5-HT2R (5-hydroxytryptamine 2 receptor) antagonist sarpogrelate and a 5-HT synthesis inhibitor, that is, the compound medicine composition can be used for treating dyslipidemia and preventing and treating AS (artherosclerosis). The compound medicine composition has the function of synergic improvement of dyslipidemia and can be used for treating diseases related with dyslipidemia, especially AS.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound pharmaceutical composition composed of a serotonin 2 receptor antagonist sagrelate and a serotonin synthesis inhibitor. The compound drug combination of the present invention can be used to treat dyslipidemia and prevent and treat atherosclerosis Like sclerosis. Background technique [0002] The main lipid forms in blood include triglyceride (Triglyceride, TG), high-density lipoprotein cholesterol (High density lipoprotein cholesterol, HDL-C), low density lipoprotein cholesterol (Low density lipoprotein cholesterol, LDL-C) and very Low-density lipoprotein cholesterol (VLDL-C). Dyslipidemia, also called hyperlipidemia and dyslipidemia, refers to the increase of blood TG, LDL-C, VLDL-C concentration (mainly manifested by TG, LDL-C increase) or HDL-C concentration caused by various reasons. The pathological manifestations of decreased concentration can also be manifested as incr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/225A61P3/06A61P9/10A61K31/198A61K31/165
Inventor 傅继华李涛郭可可屈伟李鑫安闪闪马少欣程茹候珊珊
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap